Skip to main content
NewslettersWatchlist

Arbutus Biopharma Corp(ABUS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.45
Day High3.53
Open:3.47
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
GlobeNewswire
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
GlobeNewswire
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
GlobeNewswire
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
GlobeNewswire
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Barchart
3 Outperforming Stocks to Buy With $500 Right Now
GlobeNewswire
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
GlobeNewswire
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
GlobeNewswire
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
GlobeNewswire
Arbutus to Participate in Jefferies Global Healthcare Conference
GlobeNewswire
Arbutus to Present Imdusiran Data at EASL Congress 2024
GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
GlobeNewswire
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
GlobeNewswire
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
GlobeNewswire
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Profile

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.